Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.92 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.54 |
| ▸ | ITGB2 | P05107 | 3/20 | 0.50 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.50 |
| ▸ | ITGAL | P20701 | 3/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CPB1 | P15086 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.45 |
| ▸ | REN | P00797 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29349986 | 0.99 | SLC15A2 (0.94) | SLC15A2CPB2ITGB2ICAM1ITGAL | |
| SCHEMBL30175135 | 0.96 | SLC15A2 (1.00) | SLC15A2CPB2ITGB2ICAM1ITGAL | |
| SCHEMBL22462015 | 0.96 | SLC15A2 (1.00) | SLC15A2CPB2ITGB2ICAM1ITGAL | |
| SCHEMBL19087235 | 0.96 | SLC15A2 (1.00) | SLC15A2CPB2ITGB2ICAM1ITGAL | |
| SCHEMBL25354642 | 0.95 | SLC15A2 (0.98) | SLC15A2CPB2ITGB2ICAM1ITGAL | |
| SCHEMBL28851961 | 0.95 | SLC15A2 (0.98) | SLC15A2CPB2ITGB2ICAM1ITGAL | |
| Acetic Acid SCHEMBL31696243 | 0.93 | SLC15A2 (0.94) | SLC15A2CPB2ITGB2ICAM1ITGAL | |
| SCHEMBL29352785 | 0.92 | SLC15A2 (0.92) | SLC15A2CPB2ITGB2ICAM1ITGAL | |
| Acetic Acid SCHEMBL29360257 | 0.92 | SLC15A2 (0.92) | SLC15A2CPB2ITGB2ICAM1ITGAL | |
| SCHEMBL29397091 | 0.88 | SLC15A2 (0.82) | SLC15A2CPB2ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1764 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113214377-B | Antibacterial peptide AP-64 and preparation method and application thereof | 四川大学 | 2022-10-28 | — | — | CN | claimed |
| CN-110551187-B | Chemically synthesized H7N9 avian influenza virus NA protein extracellular region antigen segment, preparation method and application | 新乡学院 | 2022-09-16 | — | — | CN | claimed |
| CN-107513103-B | MASP isoforms as inhibitors of complement activation | OMEROS CORP. (US) | 2026-05-26 | — | — | CN | disclosed |
| CN-116024225-B | Novel gene for increasing gramineous plant seed yield and application thereof | 中国科学院分子植物科学卓越创新中心 | 2026-05-12 | — | — | CN | disclosed |
| US-12617971-B2 | Anti-viral coating composition, and method for fixing anti-viral fusion protein to surfaces | AMOLIFESCIENCE CO., LTD. (KR) | 2026-05-05 | — | — | US | disclosed |
| US-20260098087-A1 | DOSAGES OF EMACTUZUMAB | Synox Therapeutics UK Limited (GB) | 2026-04-09 | — | — | US | disclosed |
| US-12486333-B2 | Tissue plasminogen activator antibodies and method of use thereof | EMSTOPA LIMITED (GB) | 2025-12-02 | — | — | US | disclosed |
| US-20250352620-A1 | COMBINATION THERAPY TO TREAT BRAIN CANCER | INOVIO PHARMACEUTICALS INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-12454573-B2 | Dosages of emactuzumab | Synox Therapeutics UK Limited (GB) | 2025-10-28 | — | — | US | disclosed |
| US-12428638-B2 | Three-component CRISPR/Cas complex system and uses thereof | THE JACKSON LABORATORY (US) | 2025-09-30 | — | — | US | disclosed |
| CN-112261874-B | Inhibition of fungal growth by manganese depletion | 科·汉森有限公司 | 2025-06-17 | — | — | CN | disclosed |
| CN-113981013-A | Biocatalytic preparation method of chiral tetrahydronaphthalene-2-alcohol compound | 寰酶生物技术(上海)有限公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-108815506-B | Application of scabies mite chitinase-like protein gene and/or protein expressed by scabies mite chitinase-like protein gene | 四川农业大学 | 2022-01-28 | — | — | CN | disclosed |
| CN-110592057-B | Chimeric lyase ILTphg and polynucleotides encoding same | 昆明理工大学 | 2022-01-28 | — | — | CN | disclosed |
| CN-113957060-A | Glutamine synthetase mutant and application thereof | 四川天豫兴禾生物科技有限公司 | 2022-01-21 | — | — | CN | disclosed |
| CN-113960313-A | Exosome ALK fusion protein magnetic immunochemiluminescence detection kit | 上海思路迪医学检验所有限公司 | 2022-01-21 | — | — | CN | disclosed |
| CN-107847592-B | Antibodies against human CSF-1R for inducing lymphocytosis in lymphomas or leukemias | 豪夫迈·罗氏有限公司 | 2022-01-21 | — | — | CN | disclosed |
| CN-113956358-A | anti-TIGIT antibodies and methods of use | 豪夫迈·罗氏有限公司 | 2022-01-21 | — | — | CN | disclosed |
| CN-113957088-A | Artificial design and application of intercellular communication system | 中国科学院微生物研究所 | 2022-01-21 | — | — | CN | disclosed |
| CN-113957061-A | Administration of kynurenine depleting enzymes for tumor therapy | 得克萨斯大学体系董事会 | 2022-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098087-A1 | DOSAGES OF EMACTUZUMAB | CSF1R, CSF3R, TNFSF11 | SLC15A2 1947/4885CPB2 2106/4885ITGB2 271/4885 |
| US-12617971-B2 | Anti-viral coating composition, and method for fixing anti-viral fusion protein to surfaces | NAPA, FES, EWSR1 | SLC15A2 3202/4885CPB2 2845/4885ITGB2 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.